A compassionate use program has also been ongoing in Israel and Romania.
Can-Fite Biopharma Says Its Phase 3 Study For Namodenoson For Advanced Liver Cancer Is 31 Recruiting Medical Centers. Namodenoson Has Orphan Drug Status From FDA And European Medicines Agency, And FDA Fast Track Status
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.